Terms: = Leukemia AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Prognosis
67 results:
1. Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion.
Li Y; Cui Q; Liu S; Liu L; Li M; Gao J; Li Z; Cui W; Zhu X; Kang L; Yu L; Wu D; Tang X
Cell Oncol (Dordr); 2024 Oct; 47(5):1649-1661. PubMed ID: 38662336
[TBL] [Abstract] [Full Text] [Related]
2. The nature inspired peptide [T20K]-kalata B1 induces anti-tumor effects in anaplastic large cell lymphoma.
Lind J; Hellinger R; Kudweis P; Moll HP; Gattringer J; Thell K; Edtmayer S; Gruber CW; Stoiber D; Kollmann K
Biomed Pharmacother; 2022 Sep; 153():113486. PubMed ID: 36076504
[TBL] [Abstract] [Full Text] [Related]
3. Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma.
Tang X; Yang ZZ; Kim HJ; Anagnostou T; Yu Y; Wu X; Chen J; Krull JE; Wenzl K; Mondello P; Bhardwaj V; Wang J; Novak AJ; Ansell SM
Clin Cancer Res; 2022 Oct; 28(19):4322-4335. PubMed ID: 35686915
[TBL] [Abstract] [Full Text] [Related]
4. Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission.
Zeng Q; Xiang B; Liu Z
Ann Hematol; 2022 Aug; 101(8):1711-1718. PubMed ID: 35570208
[TBL] [Abstract] [Full Text] [Related]
5. CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.
Perkins B; Showel M; Schoch L; Imus PH; Karantanos T; Yonescu R; Morsberger L; Ghiaur G; Gladstone DE; Jones RJ
Leuk Lymphoma; 2022 Jul; 63(7):1617-1623. PubMed ID: 35343368
[TBL] [Abstract] [Full Text] [Related]
6. Efficacy and safety of chemotherapy combined with different doses of il-2 maintenance therapies for acute myeloid leukemia: A protocol for a Bayesian network meta-analysis.
Yin X; Ding Y; Yu L; Guo C; Cui Y; Zhai X; Wang Y; Ding S; Shen M; Li Z; Xu R
Medicine (Baltimore); 2021 Jun; 100(23):e26098. PubMed ID: 34114994
[TBL] [Abstract] [Full Text] [Related]
7. Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor prognosis IGHV- Unmutated Chronic Lymphocytic leukemia.
Maharaj D; Srinivasan G; Abreu MM; Ko MW; Jewett A; Gouvea J
Cells; 2020 Dec; 10(1):. PubMed ID: 33375215
[TBL] [Abstract] [Full Text] [Related]
8. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract] [Full Text] [Related]
9. Immunorelated gene polymorphisms associated with acute myeloid leukemia.
Liu Q; Hua M; Yan S; Zhang C; Wang R; Yang X; Han F; Hou M; Ma D
Clin Exp Immunol; 2020 Sep; 201(3):266-278. PubMed ID: 32349161
[TBL] [Abstract] [Full Text] [Related]
10. [Application of CpG Oligodeoxynucleotide Immunostimulation in Chromosome Study of Chronic Lymphoblastic leukemia].
Mai DI Na AEK; Liu H; Wang YL; Wang YC; Huang Q; Wang ZS; Gu ZLNE; Lang T; Nie YL; An L; A ZGL; Mu HTBE; Zhang XY; Fu L; Ai HMJ; Mao M; Wang XM; Li Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):470-475. PubMed ID: 32319381
[TBL] [Abstract] [Full Text] [Related]
11. [Chromosomal aberrations detection in chronic lymphocytic leukemia by conventional cytogenetics using DSP30 and il-2].
Liu HF; Huang HW; Bai SX; Gong YL; Wu CX; Jin ZM; Wang YY; Yang Q; Zhang J; Qiu HY; Chen SN; Pan JL
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):143-148. PubMed ID: 32135632
[No Abstract] [Full Text] [Related]
12. Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients.
Wu K; Feng J; Xiu Y; Li Z; Lin Z; Zhao H; Zeng H; Xia W; Yu L; Xu B
Int Immunopharmacol; 2020 Mar; 80():106122. PubMed ID: 31955066
[TBL] [Abstract] [Full Text] [Related]
13. Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL.
Kannagi M; Hasegawa A; Nagano Y; Kimpara S; Suehiro Y
Retrovirology; 2019 Aug; 16(1):23. PubMed ID: 31438973
[TBL] [Abstract] [Full Text] [Related]
14. il-2/IL-3 interplay mediates growth of CD25 positive acute myeloid leukemia cells.
Nakase K; Kita K; Katayama N
Med Hypotheses; 2018 Jun; 115():5-7. PubMed ID: 29685196
[TBL] [Abstract] [Full Text] [Related]
15. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
Björklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikström K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellström-Lindberg E; Ljunggren HG; Malmberg KJ
Clin Cancer Res; 2018 Apr; 24(8):1834-1844. PubMed ID: 29444931
[No Abstract] [Full Text] [Related]
16. Synergistic therapeutic effect of diethylstilbestrol and CX-4945 in human acute T-lymphocytic leukemia cells.
Jung JI; Park KY; Kim SA; Kim J
Biomed Pharmacother; 2018 Feb; 98():357-363. PubMed ID: 29275177
[TBL] [Abstract] [Full Text] [Related]
17. Cytokines and soluble HLA-G levels in bone marrow stroma and their association with the survival rate of patients exhibiting childhood T-cell acute lymphoblastic leukemia.
Almeida RDS; Ramos AML; Luna CF; Pedrosa F; Donadi EA; Lucena-Silva N
Cytokine; 2018 Feb; 102():94-101. PubMed ID: 28802664
[TBL] [Abstract] [Full Text] [Related]
18. Galectin-9 as a Predictive Marker for the Onset of Immune-Related Adverse Effects Associated with Anti-CCR4 MoAb Therapy in Patients with Adult T Cell leukemia.
Mohammed TO; Chagan-Yasutan H; Ashino Y; Nakayama W; Takahashi Y; Shimomura T; Fujimoto T; Watanabe Y; Niki T; Suzushima H; Hattori T
Tohoku J Exp Med; 2017 Mar; 241(3):201-208. PubMed ID: 28321034
[TBL] [Abstract] [Full Text] [Related]
19. Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.
Rydström A; Hallner A; Aurelius J; Sander FE; Bernson E; Kiffin R; Thoren FB; Hellstrand K; Martner A
J Leukoc Biol; 2017 Aug; 102(2):467-474. PubMed ID: 28235771
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy of DSP30-il2/TPA for detection of cytogenetic abnormalities in chronic lymphocytic leukaemia/small lymphocytic lymphoma.
Holmes PJ; Peiper SC; Uppal GK; Gong JZ; Wang ZX; Bajaj R
Int J Lab Hematol; 2016 Oct; 38(5):483-9. PubMed ID: 27565124
[TBL] [Abstract] [Full Text] [Related]
[Next]